mTOR Cross-Talk in Cancer and Potential for Combination Therapy

Author： Conciatori Fabiana Ciuffreda Ludovica Bazzichetto Chiara Falcone Italia Pilotto Sara Bria Emilio Cognetti Francesco Milella Michele

Publisher： MDPI

E-ISSN： 2072-6694|10|1|23-23

ISSN： 2072-6694

Source： Cancers, Vol.10, Iss.1, 2018-01, pp. : 23-23

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR Pathways in Cancer and Autophagy

By Paquette Mathieu El-Houjeiri Leeanna Pause Arnim

Cancers, Vol. 10, Iss. 1, 2018-01 ,pp. : 18-18

MDPI

Access to resources Recommend Favorite

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives

By Dufour Marc Dormond-Meuwly Anne Demartines Nicolas Dormond Olivier

Cancers, Vol. 3, Iss. 2, 2011-05 ,pp. : 2478-2500

MDPI

Access to resources Recommend Favorite

The mTOR Signalling Pathway in Human Cancer

By Pópulo Helena Lopes José Manuel Soares Paula

International Journal of Molecular Sciences, Vol. 13, Iss. 2, 2012-02 ,pp. : 1886-1918

MDPI

Access to resources Recommend Favorite

mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer

By Wei Feng Zhang Yandong Geng Li Zhang Ping Wang Guangyi Liu Yan

International Journal of Molecular Sciences, Vol. 16, Iss. 2, 2015-02 ,pp. : 3267-3282

MDPI

Access to resources Recommend Favorite

Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression

By Rad Ellie Murray James T. Tee Andrew R.

Cancers, Vol. 10, Iss. 1, 2018-01 ,pp. : 5-5

MDPI

Access to resources Recommend Favorite